PDL BioPharma just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:
424B5 1 pdli-20161116424b5doc.htm 424B5 Document PROSPECTUS SUPPLEMENT As filed pursuant to Rule 424(b)(5)(To prospectus dated June 28, 2016) Registration No. 333-211970$150,000,000PDL BioPharma, Inc. 2.75% Convertible Senior Notes due 2021We are offering $150,000,000 aggregate principal amount of 2.75% Convertible Senior Notes due 2021. We will pay interest on the notes on June 1 and December 1 of each year beginning on June 1, 2017. The notes will mature on December 1, 2021, unl ess earlier repurchased or converted.Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding June 1, 2021 only under the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ending on March 31, 2017, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on each applicable trading day; (2) during the five business day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such trading day; or (3) upon the occurrence of specified corporate events. On and after June 1, 2021, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their notes at any time, regardless of the foregoing circumstances. We will settle conversions by paying or delivering, as applicable, cash, shares of our common stock or a combination of cash and shares of our
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever PDL BioPharma makes a similar move, sign up!
Other recent filings from the company include the following:
Current report, items 7.01 and 9.01
- Nov. 14, 2017
PDL BioPharma Just Filed Its Quarterly Report: 2. Net Income per Sh... - Nov. 13, 2017
Notification of inability to timely file Form 10-Q or 10-QSB - Nov. 13, 2017
Pdl Biopharma’S Proposal To Acquire Neos Therapeutics Expires Today; - Nov. 8, 2017
PDL: Cook Williams Communications, Inc - Nov. 2, 2017